Overview: Evaluation of metabolism-based drug toxicity in drug development

Chemico-Biological Interactions

Volumn 179, Issue 1, 2009, Pages 1-3

  Li, Albert P ^a  

^a In Vitro ADMET Laboratories LLC   (United States)

Author keywords

Drug metabolism; Drug toxicity; Human hepatocytes; Idiosyncratic drug toxicity; In vitro; Metabolite identification; P450; Reactive metabolites

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; DRUG METABOLIZING ENZYME; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON; XENOBIOTIC AGENT;

AMES TEST; CYTOTOXICITY; DETOXIFICATION; DRUG METABOLISM; DRUG TRANSFORMATION; EDITORIAL; GENOTOXICITY; GOOD LABORATORY PRACTICE; HUMAN; METABOLIC ACTIVATION; METABOLIC INHIBITION; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; TOXICITY TESTING; XENOBIOTIC METABOLISM;

ANIMALS; BIOTRANSFORMATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 59649098466     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.11.013     Document Type: Editorial

References (21)

1. Li A.P. Accurate prediction of human drug toxicity: a major challenge in drug development. Chem. Biol. Interact. 150 (2008) 3-7
2. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8 1 (2006) E101-E111
3. Beaune P.H., and Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J. Hepatol. 26 (1997) 37-42
4. Hanzlik R.P., Fang J., and Koen Y.M. Filling and mining the reactive metabolite target protein database. Chem. Biol. Interact. 179 (2009) 38-44
5. Ma S., and Zhu M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 179 (2009) 25-37
6. Li A.P. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact. 168 (2007) 16-29
7. Sato Y., Yamada H., Iwasaki K., Tateno C., Yokoi T., Yoshizato K., and Horii I. Human hepatocytes can repopulate mouse liver: histopathology of the liver in human hepatocyte-transplanted chimeric mice and toxiologic responses to acetaminophen. Toxicol. Pathol. 36 (2008) 581-591
8. FDA Guidance for Industry, Saftey testing of drug metabolites, Pharmcology and Toxicology, February 2008, http://www.fda.gov/cder/guidance/.
9. Smith D.A., Scott Obach R., Williams D.P., and Kevin Park B. Clearing the MIST (metabolites in safety testing) of time: the impact of duration of administration on drug metabolite toxicity. Chem. Biol. Interact. 179 (2009) 60-67
10. Pang K.S. Safety testing of metabolites: expectations and outcomes. Chem. Biol. Interact. 179 (2009) 45-59
11. Li A.P. Preclinical in vitro screening assays for drug-like properties. Drug Discov. Today 2 (2005) 79-85
12. Li A.P. Use of Aroclor 1254-induced rat liver homogenate in the assaying of promutagens in Chinese hamster ovary cells. Environ. Mutagen. 6 (1984) 539-544
13. Li A.P. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarinoma breast cancer cells. Chemico-Biol. Interact. 150 (2004) 129-136
14. Li A.P. In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology. ALTEX 25 (2008) 43-49
15. Li A.P. Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. Chemico-Biol. Interact. 179 (2009) 4-8
16. Gonzalez F.J. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol. Lett. 120 (2001) 199-208
17. Lauer B., Tuschl G., Kling M., and Mueller S.O. Species-specific toxicity of diclofenac, troglitazone in primary human and rat hepatocytes. Chemico-Biol. Interact. 179 (2009) 17-24
18. Vickers A.E.M. Tissue slices for the evaluation of metabolism-based toxicity with the example of diclofenac. Chemico-Biol. Interact. 179 (2009) 9-16
19. Li A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142 (2002) 7-23
20. Smith D.A. Commentary-Dogma driven science, the need to establish a common base line. Chemico-Biol. Interact. 179 (2009) 68-70
21. Li A.P. A comprehensive approach for drug safety assessment. Chemico-Biol. Interact. 150 (2004) 27-33